Clinical trials: Prader Labhart Willi Syndrome
Prader-Willi Syndrome
A Study of Diazoxide Choline in Patients With Prader-Willi Syndrome
The purpose of this is study is to evaluate the effects of DCCR (diazoxide choline controlled release tablets) in children and adults with Prader-Willi syndrome.
- Trial name
- NCT03440814
- Testing
- DCCR
- Where
- 29 sites in United States, United Kingdom
- Volunteers
- 127 people
- Sponsor
- Soleno Therapeutics, Inc.
Prader-Willi Syndrome, Obesity
Understanding the Role of Gut Microbiota in Hyperphagia in Prader-Willi Syndrome
This study aims to use a high-fiber supplementation, an intervention known to create shifts in the gut microbiota towards a healthier structure, to explore the relationship between gut microbiota, appetite control and feeding…
- Trial name
- PWSGUT (NCT05541003)
- Testing
- NBT-NM108
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Rutgers, The State University of New Jersey
Prader-Willi Syndrome
Tolerance of Intranasal Administration of OT in Prader-Willi Newborn Babies
Background: Prader-Willi syndrome (PWS) is a rare, complex multisystem genetic disorder arising from the lack of expression of paternally inherited imprinted genes on chromosome 15q11-q13.
- Trial name
- OTBB (NCT01548521)
- Testing
- Oxytocin
- Where
- France
- Volunteers
- 5 people
- Sponsor
- University Hospital, Toulouse
Prader-Willi Syndrome
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
This study aims to examine the feasibility and safety of cannabidivarin (CBDV) as a treatment for children and young adults with PWS.
- Trial name
- NCT03848481
- Testing
- CBDV Compound
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Eric Hollander
Prader Willi Syndrome, Childhood Obesity
Family-based Intervention for Youth With Prader-Willi Syndrome: The Active Play at Home Study
Compared to other children, those with disability have additional challenges to being physically active. Prader-Willi Syndrome (PWS) is a genetic form of childhood obesity that is characterized by hypotonia, growth hormone…
- Trial name
- APAH (NCT02058342)
- Testing
- Active Play at Home
- Where
- 2 sites in United States
- Volunteers
- 115 people
- Sponsor
- California State University, Fullerton
Prader-Willi Syndrome
Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial
This study is a prospective, multicentre, interventional cohort study in children with Prader-Willi Syndrome (PWS) over 4 years (no treatment administered). The duration of the preceding OTTB3 study is 26 weeks.
- Trial name
- OTBB3-FU (NCT05032326)
- Testing
- Follow-up study of the treated cohort, Follow-up study of the untreated cohort
- Where
- 12 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Toulouse
Obstructive Sleep Apnea (OSA), Orofacial Myofunctional Disorders
Oromyofunctional Therapy: a Rehabilitation Program for OSA in Children With Down Syndrome and Prader-Willi Syndrome
Obstructive sleep apnea (OSA) is a prevalent medical condition with important implications for overall health and quality of life in both children. Therefore, it is important to treat OSA early and effectively.
- Trial name
- OROFIT-P (NCT07122505)
- Testing
- Orofacial myofunctional therapy
- Where
- Belgium
- Volunteers
- 60 people
- Sponsor
- University Ghent
22q11 Deletion Syndrome, DiGeorge Syndrome
SNP-based Microdeletion and Aneuploidy RegisTry (SMART)
This multi-center prospective observational study is designed to track birth outcomes and perinatal correlates to the Panorama prenatal screening test in the general population among ten thousand women who present clinically and…
- Conditions
- 22q11 Deletion Syndrome, DiGeorge Syndrome, Trisomy 21, Trisomy 18
- Trial name
- SMART (NCT02381457)
- Where
- 21 sites in United States, Australia and 4 more
- Volunteers
- 20,960 people, healthy volunteers welcome
- Sponsor
- Natera, Inc.
Prader-Willi Syndrome
A Study of Oral ARD-101 in Patients With Prader-Willi Syndrome
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of ARD-101 in Patients with Prader-Willi Syndrome
- Trial name
- NCT05153434
- Testing
- ARD-101
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Aardvark Therapeutics, Inc.
Prader-Willi Syndrome
GH in Adults With PWS, Effect on Hypotonia Evaluated by Functional MRI, Relationship With Strength and Body Composition
Prader-Willi syndrome (PWS) is a genetic disorder associated with growth hormone (GH) deficiency, central hypotonia and hyperphagia that leads to life-threatening obesity.
- Trial name
- NCT03616509
- Testing
- Growth hormone
- Where
- Spain
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
Prader-Willi Syndrome
Growth Hormone Use in Adults With Prader-Willi Syndrome
The main research question this protocol aims to answer is whether treatment with growth hormone will impact body composition, quality of life, and energy balance in PWS adults, and if there is a loss of effects after cessation…
- Trial name
- NCT00444964
- Testing
- Nutropin AQ
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Children's Mercy Hospital Kansas City
Prader-Willi Syndrome
Autistic Symptomatology and Sensory Profile in Children With Prader-Willi Syndrome
Prader-Willi Syndrome (PWS) is a rare neurodevelopmental disorder stemming from genetic damage in the 15q11-q13 region, leading to hypothalamic dysfunction.
- Trial name
- CASSPER (NCT06877715)
- Testing
- psychological and sensorial tests
- Where
- France
- Volunteers
- 75 people
- Sponsor
- University Hospital, Toulouse
Prader-Willi Syndrome
An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001)
A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Prader-Willi Syndrome.
- Trial name
- PWS-001 (NCT05879614)
- Testing
- NNZ-2591
- Where
- 4 sites in United States
- Sponsor
- Neuren Pharmaceuticals Limited
Hyperphagia in Prader-Willi Syndrome
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
12-week, randomized, double-blind, placebo-controlled, parallel-group study of carbetocin nasal spray for the treatment of hyperphagia in Prader-Willi syndrome (PWS)
- Trial name
- NCT06173531
- Testing
- Carbetocin
- Where
- 30 sites in United States, Canada and 4 more
- Volunteers
- 175 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Hyperphagia in Prader-Willi Syndrome
OLE Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
To evaluate long-term safety and tolerability of carbetocin nasal spray (3.2 mg TID) in subjects with PWS
- Trial name
- NCT06420297
- Testing
- Carbetocin
- Where
- 30 sites in United States, Canada and 4 more
- Volunteers
- 168 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Sleep Disorder, Hyperphagia
Effect of Deep Propioceptive Stimulation in Prader-Willi Syndrome
The main objective is to study the effect of deep propioceptive stimulation with a heavy blanket for 2 weeks compared with a placebo blanket on sleep quality and behavior in patients with PWS
- Conditions
- Sleep Disorder, Hyperphagia, Behavior Disorders
- Trial name
- NCT05044000
- Testing
- Deep propioceptive stimulation
- Where
- Spain
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Corporacion Parc Tauli
Prader-Willi Syndrome, Excessive Daytime Sleepiness
Impact of Bright Light Therapy on Prader-Willi Syndrome
This is a placebo controlled clinical trial to assess the utility of light therapy as a sufficient treatment for excessive daytime sleepiness in patients with Prader-Willi Syndrome
- Conditions
- Prader-Willi Syndrome, Excessive Daytime Sleepiness, Hyperphagia, Body Weight
- Trial name
- PWS-LT (NCT05939453)
- Testing
- Bright Light Therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Maimonides Medical Center
Prader-Willi Syndrome, Hyperphagia
Fiber Intervention on Gut Microbiota in Children With Prader-Willi Syndrome
Prader-Willi syndrome (PWS) is the most common syndromic cause of obesity. Individuals with PWS characteristically experience excessive weight gain and severe hyperphagia with food compulsivity in early childhood, which often…
- Trial name
- NCT04150991
- Testing
- Fiber intervention
- Where
- Canada
- Volunteers
- 14 people
- Sponsor
- University of Alberta
Prader-Willi Syndrome
Effect of Intranasal Oxytocin on Dysphagia in Children and Adolescents With Prader-Willi Syndrome
This phase 2B is designed to test the effectiveness of intranasal Oxytocin on Prader Willi Syndrome (PWS). This is a prospective, multicentre, randomised, double-blind, Phase 2B clinical study planned to include around 24 PWS…
- Trial name
- DYSMOT (NCT05298085)
- Testing
- Oxytocin nasal spray
- Where
- 4 sites in France
- Volunteers
- 25 people
- Sponsor
- University Hospital, Toulouse
Prader-Willi Syndrome, Obesity
Plasma Adiponectin Level and Sleep Structures in Children With Prader-Willi Syndrome
Context: Adiponectin is an adipose tissue-derived hormone with an insulin sensitizing effect, and has been related to obstructive sleep apnea syndrome.
- Trial name
- NCT01622751
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Samsung Medical Center